

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



9606642-3
1805
copy's

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 263/56, 263/32, C07C 229/36, A61K 31/42, C07D 333/36, C07C 235/30, C07D 295/18, 413/04, 413/12, 277/24, 235/12, 231/12, 417/12, 277/42, 207/08	A1	(11) International Publication Number: WO 97/31907
		(43) International Publication Date: 4 September 1997 (04.09.97)

(21) International Application Number: PCT/EP97/00916

(22) International Filing Date: 26 February 1997 (26.02.97)

(30) Priority Data:
9604242.9 28 February 1996 (28.02.96) GB

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WILLSON, Timothy, Mark [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). MOOK, Robert, Anthony, Jr. [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). KALDOR, Istvan [HU/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). HENKE, Brad, Richard [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). DEATON, David, Norman [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). COLLINS, Jon, Loren [US/US]; Glaxo Wellcome Inc., Five Moore Drive,

Research Triangle Park, NC 27709 (US). COBB, Jeffrey, Edmond [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). BRACKEEN, Markus [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). SHARP, Matthew, Jude [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). O'CALLAGHAN, John, Mark [GB/GB]; Glaxo Wellcome Plc, Temple Hill, Dartford, Kent DA1 5AH (GB). ERICKSON, Greg, Alan [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). BOSWELL, Grady, Evan [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).

(74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA

(57) Abstract

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C₁-alkyl, C₁-alkoxy, C₁-fluoroalkoxy, nitrile, or -NR⁷R⁸ where R⁷ and R⁸ are independently hydrogen or C₁-alkyl; (ii) a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C₁-alkylene; (v) -MC₁-alkylene or C₁-alkyleneMC₁-alkylene, wherein M is O, S, or -NR² wherein R² represents hydrogen or C₁-3 alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C₁-3 alkyl; and (vii) Het-C₁-alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C₁-3alkylene; R¹ represents hydrogen or C₁-3alkyl; Z is selected from the group consisting of: (viii) -(C₁-3alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) -NR³R⁴, wherein R³ represents hydrogen or C₁-3alkyl, and R⁴ represents -Y-(C=O)-T-R⁵, or -Y-(CH(OH))-T-R⁵.

